174 related articles for article (PubMed ID: 30496458)
1. Artificial intelligence-derived 3-Way Concentration-dependent Antagonism of Gatifloxacin, Pyrazinamide, and Rifampicin During Treatment of Pulmonary Tuberculosis.
Pasipanodya JG; Smythe W; Merle CS; Olliaro PL; Deshpande D; Magombedze G; McIlleron H; Gumbo T
Clin Infect Dis; 2018 Nov; 67(suppl_3):S284-S292. PubMed ID: 30496458
[TBL] [Abstract][Full Text] [Related]
2. Concentration-Dependent Antagonism and Culture Conversion in Pulmonary Tuberculosis.
Rockwood N; Pasipanodya JG; Denti P; Sirgel F; Lesosky M; Gumbo T; Meintjes G; McIlleron H; Wilkinson RJ
Clin Infect Dis; 2017 May; 64(10):1350-1359. PubMed ID: 28205671
[TBL] [Abstract][Full Text] [Related]
3. Effects on the QT Interval of a Gatifloxacin-Containing Regimen versus Standard Treatment of Pulmonary Tuberculosis.
Olliaro PL; Merle C; Mthiyane T; Bah B; Kassa F; Amukoye E; N Diaye A; Perronne C; Lienhardt C; McIlleron H; Fielding K
Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28438924
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of initial and steady-state gatifloxacin pharmacokinetics and dose in pulmonary tuberculosis patients by using monte carlo simulations.
Smythe W; Merle CS; Rustomjee R; Gninafon M; Lo MB; Bah-Sow O; Olliaro PL; Lienhardt C; Horton J; Smith P; McIlleron H; Simonsson US
Antimicrob Agents Chemother; 2013 Sep; 57(9):4164-71. PubMed ID: 23774436
[TBL] [Abstract][Full Text] [Related]
5. Serum drug concentrations predictive of pulmonary tuberculosis outcomes.
Pasipanodya JG; McIlleron H; Burger A; Wash PA; Smith P; Gumbo T
J Infect Dis; 2013 Nov; 208(9):1464-73. PubMed ID: 23901086
[TBL] [Abstract][Full Text] [Related]
6. Effect of Metformin on Plasma Exposure of Rifampicin, Isoniazid, and Pyrazinamide in Patients on Treatment for Pulmonary Tuberculosis.
Kumar AKH; Kadam A; Karunaianantham R; Tamizhselvan M; Padmapriyadarsini C; Mohan A; Jeyadeepa B; Radhakrishnan A; Singh UB; Bapat S; Mane A; Kumar P; Mamulwar M; Bhavani PK; Haribabu H; Rath N; Guleria R; Khan AM; Menon J;
Ther Drug Monit; 2024 Jun; 46(3):370-375. PubMed ID: 38019456
[TBL] [Abstract][Full Text] [Related]
7. A four-month gatifloxacin-containing regimen for treating tuberculosis.
Merle CS; Fielding K; Sow OB; Gninafon M; Lo MB; Mthiyane T; Odhiambo J; Amukoye E; Bah B; Kassa F; N'Diaye A; Rustomjee R; de Jong BC; Horton J; Perronne C; Sismanidis C; Lapujade O; Olliaro PL; Lienhardt C;
N Engl J Med; 2014 Oct; 371(17):1588-98. PubMed ID: 25337748
[TBL] [Abstract][Full Text] [Related]
8. Drug Concentration Thresholds Predictive of Therapy Failure and Death in Children With Tuberculosis: Bread Crumb Trails in Random Forests.
Swaminathan S; Pasipanodya JG; Ramachandran G; Hemanth Kumar AK; Srivastava S; Deshpande D; Nuermberger E; Gumbo T
Clin Infect Dis; 2016 Nov; 63(suppl 3):S63-S74. PubMed ID: 27742636
[TBL] [Abstract][Full Text] [Related]
9. Effect of Diabetes Mellitus on the Pharmacokinetics and Pharmacodynamics of Tuberculosis Treatment.
Alfarisi O; Mave V; Gaikwad S; Sahasrabudhe T; Ramachandran G; Kumar H; Gupte N; Kulkarni V; Deshmukh S; Atre S; Raskar S; Lokhande R; Barthwal M; Kakrani A; Chon S; Gupta A; Golub JE; Dooley KE
Antimicrob Agents Chemother; 2018 Nov; 62(11):. PubMed ID: 30126955
[TBL] [Abstract][Full Text] [Related]
10. Elevated gatifloxacin and reduced rifampicin concentrations in a single-dose interaction study amongst healthy volunteers.
McIlleron H; Norman J; Kanyok TP; Fourie PB; Horton J; Smith PJ
J Antimicrob Chemother; 2007 Dec; 60(6):1398-401. PubMed ID: 17951604
[TBL] [Abstract][Full Text] [Related]
11. HIV-1 Coinfection Does Not Reduce Exposure to Rifampin, Isoniazid, and Pyrazinamide in South African Tuberculosis Outpatients.
Rockwood N; Meintjes G; Chirehwa M; Wiesner L; McIlleron H; Wilkinson RJ; Denti P
Antimicrob Agents Chemother; 2016 Oct; 60(10):6050-9. PubMed ID: 27480859
[TBL] [Abstract][Full Text] [Related]
12. Isoniazid, rifampicin and pyrazinamide plasma concentrations 2 and 6 h post dose in patients with pulmonary tuberculosis.
Fahimi F; Tabarsi P; Kobarfard F; Bozorg BD; Goodarzi A; Dastan F; Shahsavari N; Emami S; Habibi M; Salamzadeh J
Int J Tuberc Lung Dis; 2013 Dec; 17(12):1602-6. PubMed ID: 24200276
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of dried blood spot sampling for pharmacokinetic research and therapeutic drug monitoring of anti-tuberculosis drugs in children.
Martial LC; Kerkhoff J; Martinez N; Rodríguez M; Coronel R; Molinas G; Roman M; Gomez R; Aguirre S; Jongedijk E; Huisman J; Touw DJ; Pérez D; Chaparro G; Gonzalez F; Aarnoutse RE; Alffenaar JW; Magis-Escurra C
Int J Antimicrob Agents; 2018 Jul; 52(1):109-113. PubMed ID: 29751121
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and tolerability of a higher rifampin dose versus the standard dose in pulmonary tuberculosis patients.
Ruslami R; Nijland HM; Alisjahbana B; Parwati I; van Crevel R; Aarnoutse RE
Antimicrob Agents Chemother; 2007 Jul; 51(7):2546-51. PubMed ID: 17452486
[TBL] [Abstract][Full Text] [Related]
15. High Intrapulmonary Rifampicin and Isoniazid Concentrations Are Associated With Rapid Sputum Bacillary Clearance in Patients With Pulmonary Tuberculosis.
McCallum AD; Pertinez HE; Chirambo AP; Sheha I; Chasweka M; Malamba R; Shani D; Chitani A; Mallewa JE; Meghji JZ; Ghany JF; Corbett EL; Gordon SB; Davies GR; Khoo SH; Sloan DJ; Mwandumba HC
Clin Infect Dis; 2022 Oct; 75(9):1520-1528. PubMed ID: 35325074
[TBL] [Abstract][Full Text] [Related]
16. [Effectiveness and problems of PZA-containing 6-month regimen for the treatment of new pulmonary tuberculosis patients].
Wada M
Kekkaku; 2001 Jan; 76(1):33-43. PubMed ID: 11211781
[TBL] [Abstract][Full Text] [Related]
17. Oral bioavailability of rifampicin, isoniazid, ethambutol, and pyrazinamide in a 4-drug fixed-dose combination compared with the separate formulations in healthy Chinese male volunteers.
Xu J; Jin H; Zhu H; Zheng M; Wang B; Liu C; Chen M; Zhou L; Zhao W; Fu L; Lu Y
Clin Ther; 2013 Feb; 35(2):161-8. PubMed ID: 23410999
[TBL] [Abstract][Full Text] [Related]
18. Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis.
Dawson R; Diacon AH; Everitt D; van Niekerk C; Donald PR; Burger DA; Schall R; Spigelman M; Conradie A; Eisenach K; Venter A; Ive P; Page-Shipp L; Variava E; Reither K; Ntinginya NE; Pym A; von Groote-Bidlingmaier F; Mendel CM
Lancet; 2015 May; 385(9979):1738-1747. PubMed ID: 25795076
[TBL] [Abstract][Full Text] [Related]
19. Comparative bioavailability of rifampicin, isoniazid and pyrazinamide from a four drug fixed dose combination with separate formulations at the same dose levels.
Agrawal S; Singh I; Kaur KJ; Bhade SR; Kaul CL; Panchagnula R
Int J Pharm; 2004 May; 276(1-2):41-9. PubMed ID: 15113612
[TBL] [Abstract][Full Text] [Related]
20. Determinants of rifampin, isoniazid, pyrazinamide, and ethambutol pharmacokinetics in a cohort of tuberculosis patients.
McIlleron H; Wash P; Burger A; Norman J; Folb PI; Smith P
Antimicrob Agents Chemother; 2006 Apr; 50(4):1170-7. PubMed ID: 16569826
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
